Real-World Analysis Of Clinical And Economic Impact Of 21-Gene Recurrence Score (Rs) Testing In Early-Stage Breast Cancer (Esbc) In Ireland.

Lynda M McSorley,Fathiya Al Rahbi,Mehala Tharmabala,Denis Evoy,James G. Geraghty,Ruth Prichard,Jane Rothwell,Damian McCartan,Enda McDermott,Maccon M. Keane,John Kennedy,Seamus O'Reilly,Steve Millen,John Crown,Lillian Mary Smyth,Catherine Margaret Kelly,Cecily Quinn,Janice Maria Walshe

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 4|浏览66

暂无评分

摘要

540Background: Treatment of hormone receptor positive (HR+) ESBC is evolving. The use of chemotherapy (CT) is declining with use of the 21-gene RS assay. This validated tool predicts the likelihood...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要